tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AstraZeneca’s New Study on Personalized Asthma Treatments in China: Market Implications
Company AnnouncementsAstraZeneca’s New Study on Personalized Asthma Treatments in China: Market Implications
11h ago
AZN
AstraZeneca’s Asthma Study Completion: Market Implications and Insights
PremiumCompany Announcements
AstraZeneca’s Asthma Study Completion: Market Implications and Insights
11h ago
AZN
AstraZeneca’s Promising Phase IIb Study on AZD3427: Market Implications
PremiumCompany Announcements
AstraZeneca’s Promising Phase IIb Study on AZD3427: Market Implications
11h ago
AZN
PRXL
Barclays says Merck/AstraZeneca earnings neutral to Moderna, negative to Ionis
PremiumThe Fly
Barclays says Merck/AstraZeneca earnings neutral to Moderna, negative to Ionis
1d ago
AZN
MRK
AstraZeneca’s Calquence Study: Evaluating Safety in Real-World CLL Treatment
PremiumCompany Announcements
AstraZeneca’s Calquence Study: Evaluating Safety in Real-World CLL Treatment
1d ago
AZN
AstraZeneca’s New Study on Trastuzumab Deruxtecan: Potential Market Impact
PremiumCompany AnnouncementsAstraZeneca’s New Study on Trastuzumab Deruxtecan: Potential Market Impact
1d ago
AZN
AstraZeneca’s COPD Study: Potential Market Impact of New Inhaler Treatments
Premium
Company Announcements
AstraZeneca’s COPD Study: Potential Market Impact of New Inhaler Treatments
1d ago
AZN
AstraZeneca’s New Study on Volrustomig: A Potential Breakthrough in Cervical Cancer Treatment
Premium
Company Announcements
AstraZeneca’s New Study on Volrustomig: A Potential Breakthrough in Cervical Cancer Treatment
1d ago
AZN
AstraZeneca’s Nexium Study: Potential Market Game-Changer for Pediatric Erosive Esophagitis
PremiumCompany Announcements
AstraZeneca’s Nexium Study: Potential Market Game-Changer for Pediatric Erosive Esophagitis
1d ago
AZN
MDSO
AstraZeneca’s ROSY-O Study: Extending Benefits of Olaparib for Oncology Patients
PremiumCompany Announcements
AstraZeneca’s ROSY-O Study: Extending Benefits of Olaparib for Oncology Patients
1d ago
AZN
AstraZeneca’s LYNPARZA Study: Key Insights for Investors
PremiumCompany Announcements
AstraZeneca’s LYNPARZA Study: Key Insights for Investors
1d ago
AZN
AstraZeneca sees FY25 core EPS to increase by low double-digit percentage
PremiumThe Fly
AstraZeneca sees FY25 core EPS to increase by low double-digit percentage
2d ago
AZN
AstraZeneca reports Q2 core EPS $2.17, up 12% at CER
PremiumThe FlyAstraZeneca reports Q2 core EPS $2.17, up 12% at CER
2d ago
AZN
AstraZeneca Reports Strong H1 2025 Results and Announces Major US Investment
Premium
Company Announcements
AstraZeneca Reports Strong H1 2025 Results and Announces Major US Investment
2d ago
Trump administration mulls charging patent holders 1%-5% fee, WSJ reports
Premium
The Fly
Trump administration mulls charging patent holders 1%-5% fee, WSJ reports
2d ago
AZN
BMY
AstraZeneca’s Phase 4 Study on Trastuzumab Deruxtecan: Safety Insights for Indian Patients
PremiumCompany Announcements
AstraZeneca’s Phase 4 Study on Trastuzumab Deruxtecan: Safety Insights for Indian Patients
2d ago
AZN
AstraZeneca’s Innovative Study on Bladder Cancer: A Potential Game-Changer
PremiumCompany Announcements
AstraZeneca’s Innovative Study on Bladder Cancer: A Potential Game-Changer
2d ago
AZN
AstraZeneca’s NIAGARA-2 Study: A New Frontier in Bladder Cancer Treatment
PremiumCompany Announcements
AstraZeneca’s NIAGARA-2 Study: A New Frontier in Bladder Cancer Treatment
2d ago
AZN
AstraZeneca’s Acalabrutinib Study: Real-World Insights for CLL Treatment
PremiumCompany Announcements
AstraZeneca’s Acalabrutinib Study: Real-World Insights for CLL Treatment
2d ago
AZN
AstraZeneca’s New Asthma Treatment Study Completes: Market Implications
PremiumCompany AnnouncementsAstraZeneca’s New Asthma Treatment Study Completes: Market Implications
2d ago
AZN
PRXL
AstraZeneca’s Phase III NSCLC Study: A Potential Game-Changer in Cancer Treatment
Premium
Company Announcements
AstraZeneca’s Phase III NSCLC Study: A Potential Game-Changer in Cancer Treatment
2d ago
AZN
AstraZeneca’s Observational Study on NSCLC Treatment Patterns in Russia: Key Insights for Investors
Premium
Company Announcements
AstraZeneca’s Observational Study on NSCLC Treatment Patterns in Russia: Key Insights for Investors
2d ago
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >